Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5AWK1)

Drug Name

NKP-1339 Drug Info

Synonyms

197723-00-5; KP-1339; EX-A1916; BCP26252; Z-3126; 1H-indazole; tetrachlororuthenium(1-) sodium salt

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Patented Agent(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Stress-activated protein kinase JNK1 (JNK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[4]
PMID25991433-Compound-F2	DM37VIQ	N. A.	N. A.	Patented	[4]
7-azaindole derivative 1	DMQL5B7	N. A.	N. A.	Patented	[4]
7-azaindole derivative 5	DMV3H98	N. A.	N. A.	Patented	[4]
PMID25991433-Compound-P6	DMNDVC9	N. A.	N. A.	Patented	[4]
PMID25991433-Compound-J3	DM17P3F	N. A.	N. A.	Patented	[4]
PMID25991433-Compound-P1	DMD8AX6	N. A.	N. A.	Patented	[4]
PMID25991433-Compound-O3	DMVOWS5	N. A.	N. A.	Patented	[4]
PMID25991433-Compound-L1	DM2135Y	N. A.	N. A.	Patented	[4]
PMID25991433-Compound-J2	DMZSOCK	N. A.	N. A.	Patented	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Endoplasmic reticulum chaperone BiP (HSPA5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SAM-6	DMDHQYA	Melanoma	2C30	Phase 1	[5]
IT-139	DMBPV9W	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Endoplasmic reticulum chaperone BiP (HSPA5)	TTW26OG	BIP_HUMAN	Inhibitor	[2]
Stress-activated protein kinase JNK1 (JNK1)	TT0K6EO	MK08_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01415297) Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors. U.S. National Institutes of Health.
2	NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer. BMC Pharmacol Toxicol. 2012; 13(Suppl 1): A82.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1496).
4	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
5	A new tumor-specific variant of GRP78 as target for antibody-based therapy. Lab Invest. 2008 Apr;88(4):375-86.